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Abstract Mesenchymal stem cells (MSC) are promis-
ing candidates for use as a biological therapeutic. Since
locally injected MSC disappear within a few weeks, we
hypothesize that efficacy of MSC can be enhanced by
prolonging their presence. Previously, encapsulation in
alginate was suggested as a suitable approach for this
purpose. We found no differences between the two
alginate types, alginate high in mannuronic acid (High
M) and alginate high in guluronic acid (High G), re-
garding MSC viability, MSC immunomodulatory
capability, or retention of capsule integrity after subcu-
taneous implantation in immune competent rats. High G
proved to be more suitable for production of injectable
beads. Firefly luciferase-expressing rat MSC were used
to track MSC viability. Encapsulation in high G alginate
prolonged the presence of metabolically active allogenic
MSC in immune competent rats with monoiodoacetate-
induced osteoarthritis for at least 8 weeks. Encapsula-
tion of humanMSC for local treatment by intra-articular
injection did not significantly influence the effect on
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Statement of significance We describe the evaluation of a
method to encapsulate human mesenchymal stem cells in small,
injectable hydrogel beads. Alginate hydrogel is used as a carrier
and protective barrier for stem cells, thus improving the
therapeutic use of (allogeneic) stem cells—based on their known
capacity to secrete factors that modulate the diseased environment.
The work contains extensive in vitro and in vivo evaluations of
survival and functionality of the encapsulated cells. With a novel
in vivo imaging approach, we longitudinally followed the fate of
the beads. Next to their use in osteoarthritis, which we evaluated in
our final tests, this can be used for other local degenerative
diseases such as myocardial infarction, macular degeneration, or
diabetic ulcers.
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pain, synovial inflammation, or cartilage damage in this
disease model. MSC encapsulation in alginate allows
for an injectable approach which prolongs the presence
of viable cells subcutaneously or in an osteoarthritic
joint. Further fine tuning of alginate formulation and
effective dosage for might be required in order to im-
prove therapeutic efficacy depending on the target
disease.
Keywords Cell encapsulation . Cell therapy . Alginate .
Mesenchymal stem cells . In vivo longitudinal imaging
Introduction
Application of mesenchymal stem cells (MSC) is prom-
ising due to their ability to influence their (micro-)
environment by secreting trophic mediators (Caplan
2017; Kinnaird et al. 2004; Timmers et al. 2011; Le
Blanc and Mougiakakos 2012; Prockop 2009; Ren
et al. 2008). These secreted factors have been demon-
strated to counteract inflammatory and catabolic pro-
cesses and attract endogenous repair cells in various
pathological conditions (van Buul et al. 2012; Estrada
et al. 2009; Timmers et al. 2011; Prockop and Oh 2012).
MSC-secreted factors have been shown to improve
cardiac function after myocardial infarction in pigs
(Timmers et al. 2011), improve lower limb movement
after spinal cord ischemia in rats (Takahashi et al. 2018),
ameliorate limb ischemia in mice (Huang et al. 2014),
and reduce pain in a murine osteoarthritis (OA) model
(Khatab et al. 2018b). Previously, it was demonstrated
that although injection of MSC has beneficial effects,
the MSC themselves are no longer detectable 3 weeks
after intra-articular injection (Diekman et al. 2013; Mak
et al. 2016). We hypothesize that the efficacy of MSC
can be enhanced by prolonging their local presence by
enabling longevity through encapsulation in a
biomaterial.
Alginate is widely used in tissue engineering and
drug delivery because of its biocompatibility, stability,
non-antigenicity, and chelating ability (reviewed in Sun
and Tan (2013); Lee and Mooney (2012)). This com-
monly used gel for cell encapsulation provides protec-
tion of the encapsulated cells against the host’s immune
system, and at the same time retains cells at the desired
location, by acting as a mechanical barrier. The in-
creased cell retention and cell survival can result in an
enhanced therapeutic efficacy at the local site of the
disease (Levit et al. 2013; Serra et al. 2011). Besides
providing a barrier for cells, alginate allows for the
release of growth factors and cytokines produced by
the encapsulated cells to the microenvironment and vice
versa. Cytokines from the microenvironment can reach
the encapsulated cells. This provides a setting for dy-
namic cross talk between cells and their environment
(Sun and Tan 2013; Choi et al. 2018; Shoichet et al.
1996). Furthermore, by encapsulating cells in alginate,
we may create a safer way for using allogeneic cells as
an alternative to autologous grafts by shielding them
from the host’s immune system (Leijs et al. 2017;
Duvivier-Kali et al. 2001; de Vos et al. 2006). This
would greatly enhance the clinical translatability of
MSC-based therapies. We have previously shown that
allogenic MSC encapsulated in alginate could survive
locally after subcutaneous implantation in vivo and
could act as an interactive immunomodulatory release
system for at least 5 weeks in vitro, hereby emphasizing
the possible advantages of this approach (Leijs et al.
2017).
The variety in composition and production methods
of different alginates has a major effect on its biocom-
patibility, stability, non-antigenicity, and chelating abil-
ity (Lee and Mooney 2012). Therefore, the first objec-
tive of this work was to find the most suitable clinical
grade alginate for MSC encapsulation to enable their
longevity in vivo, while maintaining anti-inflammatory
and tissue-modulating capacities. Alginate consists of a
combination of β-D-mannuronic acid and α-L-
guluronic acid. We compared two alginates, one
consisting of a high concentration of β-D-mannuronic
acid (High M alginate) and the other with high concen-
tration of α-L-guluronic acid (High G alginate). The
alginates were evaluated regarding their effect on cell
survival, preservation of immunomodulatory function
of the MSC, and histocompatibility using a set of
in vitro assays and in vivo tests. One alginate formula-
tionwas selected to reproducibly produce small beads of
injectable size. Then, we tested the prolonged presence
of MSC and alginate microcapsules as well as their
therapeutic efficacy in a local disease model.
Injection ofMSC has been shown to diminish several
features of osteoarthritis (OA) in pre-clinical and some
initial clinical studies (Ter Huurne et al. 2012; Murphy
et al. 2003; van Buul et al. 2014; Lamo-Espinosa et al.
2016; Gupta et al. 2016; Pers et al. 2016). OA is a
degenerative disabling joint disease, characterized by
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loss of cartilage integrity, subchondral bone changes,
formation of osteophytes, and inflammation of the sy-
novial membrane (Zhang and Jordan 2010). Unfortu-
nately, to this date, no curative treatment for OA exists,
while OA is a growing problem in society, already
affecting over 10% of individuals aged 60 years or older
(Zhang and Jordan 2010). We evaluated whether encap-
sulation in alginate could prolong the local presence of
allogeneic MSC in an immunocompetent rat OAmodel,
using longitudinal bioluminescence imaging (BLI) and
we followed the structural integrity of the alginate beads
after injection in the knee of rats via longitudinal MRI.
Since pain and functional disability are the main reasons
for patients to seek medical treatment, we evaluated the
efficacy of encapsulation of MSC in alginate beads to
reduce pain as well as cartilage damage and synovial
inflammation in a rat model of OA.
Materials and methods
Expansion of rat and human mesenchymal stem cells
Allogeneic rat MSC (rMSC) were used for cell tracking
experiments in vivo. rMSC were isolated (with ethical
approval under animal ethical no. EMC 116-12-08)
from 3 to 4 months old male Lewis rats (Janvier labs)
as described elsewhere and expanded up to passage 3
(Farrell et al. 2006), to be used for subcutaneous in vivo
experiments. For in vivo cell tracking experiment in the
joint, we used allogeneic F344 rat MSC (Millipore,
Billerica, MA) that were transduced to express firefly
luciferase (r(Fluc)MSCs) as described before (van Buul
et al. 2014; Guenoun et al. 2013).
Human bone marrow MSC (hMSC) were used to
evaluate therapeutic efficacy in vitro and in vivo. Cells
were derived from 6 patients undergoing total hip re-
placement (mean age 49 ± 11.2 years; F:M ratio, 1:1) by
needle aspiration after written informed consent and
approval by the medical ethical committee (Erasmus
MC protocol METC-2004-142 and Albert Schweizer
Hospital protocol 2011-07). Bone marrow cells were
plated at 50,000 cells/cm2 and after 24 h flasks were
washed to remove non-adherent cells and cells were
further cultured and expanded as described below for a
maximum of 4 passages.
For cell expansion, both rat and human MSC were
seeded at a density of 2300 cells/cm2 in cell culturing
flasks, in expansion medium consisting of Minimal
Essential Medium Alpha (αMem; Gibco, Rockville,
USA), 10% heat-inactivated Fetal Calf Serum (FCS;
Gibco, Rockville, USA), 1.5 μg/mL fungizone
(Invitrogen, Carlsbad, USA), 50 μg/mL gentamicin
(Invitrogen, Carlsbad, USA), 25 μg/mL ascorbic acid-
2-phosphate (Sigma-Aldrich, Saint Louis, USA), and 1
ng/mL Fibroblast Growth Factor 2 (FGF2; AbD
Serotec, Oxford, UK). Cells were cultured in an incuba-
tor at 37 °C, 5% CO2, and 90% humidity. Medium was
renewed twice a week. When MSCs were approximate-
ly 70% confluent, they were passaged by trypsinization
of cells with a 0.25% trypsin/EDTA solution (Life Tech-
nologies, Waltham, USA).
Preparation of MSC-alginate constructs
Clinical-grade high mannuronate (M) alginate (Lami-
naria pallida) and high guluronate (G) alginate (Lami-
naria hyperborea) (respectively; Lot no. E01 AAL-
070912 and Lot no. C01 AAL-110808 both kind gifts
of BTG/CellMed AG, Alzenau, Germany) were used.
Both alginates were diluted in a 0.5%, 1.1%, and 2.5%
concentration in NaCl 0.9% and filter-sterilized after-
wards. The shear-dependent viscosity of the solutions
was measured by a rheometer Physica MCR301 (Anton
Paar GmbH, Ostfildern, Germany) at room temperature
(20 °C). The viscosity was measured in a shear rate
range of 1–5000 s-1 by increasing the shear rate every
5 s for a duration of 2 min and 45 s. Data were analyzed
with Rheoplus Software version 3.4 (Anton Paar
GmbH, Ostfildern, Germany). For 1.1% High M algi-
nate, the low shear viscosity at 20 °C was found to be
1320 mPa s; for 1.1% High G alginate, the low shear
viscosity at 20 °C was 274 mPa s. The effect of shear
stress on the viscosity was similar for both alginates.
Prior to encapsulation, MSC were washed with sa-
line. A homogeneous solution of 4.0 × 106 MSC per 1
mL filter-sterilized 1.1% High M alginate or 1.1% High
G alginate was prepared. This cell density was selected
after a series of tests comparing 0.4, 4, and 20 million
cells/mL, indicating that 4 million cells/mL was the
most efficient cell number in terms of cell viability and
immunomodulatory properties during 2 weeks encapsu-
lation in alginate in vitro (data not shown).
Beads of approximately 2 mm in diameter were
created by manually dripping the MSC-alginate mixture
through a 23-gauge needle in 102 mM CaCl2 solution
for 10 min. After incubation, beads were washed two
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times for 5 min with saline before further use in in vitro
experiments.
For subcutaneous implantation, alginate disks were
created by polymerization of the rMSC-alginate solu-
tion which took place in a sterilized, custom-designed
mold consisting of two durapore membranes (5-μm
pore size, Millipore) at both sides of a 3-mm-thick metal
ring (Wong et al. 2001). After 30 min in 102 mMCaCl2,
the construct was washed two times in saline and 8-mm-
diameter constructs were made with sterile dermal
punches (Spengler, Hanover, Germany).
To produce smaller beads in a more reproducible
way, we used the Buchi Encapsulator B-395 Pro (Buchi
Labortechnik AG, Flawil, Switzerland). After optimiz-
ing the settings, beads of approximately 300 μm in
diameter were made from 1.1% High G alginate with
the following machine settings: flow rate 3 mL/min,
nozzle size 150 μm, frequency 1600 Hz, voltage 730
V, stir-rate 30% speed. To be able to track the alginate
beads using MRI in vivo, we solidified the alginate
solution with 102 mM CaCl2 with 20 mM gadolinium
(III) chloride hexahydrate (Lot no. MKBJ3153V, Sig-
ma-Aldrich, St. Louis, USA). Beads were kept in this
solution for 10 min, then washed twice with saline
solution, and kept for a maximum of 4 h in saline prior
to injection.
In vitro characterization of MSC-alginate constructs
Three hMSC-alginate beads were placed in 24-well
plates in 900 μL of medium consisting of αMem with
fungizone (1.5 μg/mL), gentamicin (50 μg/mL), 1%
insulin-transferrin-selenium (ITS; Biosciences, New
Jersey, USA), and 0.1 mM vitamin C (Sigma, St. Louis,
MO). Medium was refreshed twice a week. Beads were
harvested directly after encapsulation and washing with
saline (T = 0), after 1 week (T = 1), and 2 weeks of
culture (T = 2) to determine cell viability and immuno-
modulatory capacity.
Cell viability
Survival of encapsulated hMSC was measured by the
amount of DNA and LIVE/DEAD® assay at T = 0 and
T = 2 weeks (using cells from 2 different bone marrow
donors). For DNA analyses, six beads were harvested at
each time point and dissolved in 150 μL/bead. Sodium-
citrate buffer (150 mMNaCl (Sigma-Aldrich, St. Louis,
USA), 55 mM Na-citrate (Sigma-Aldrich), 20 mM
EDTA (Sigma-Aldrich)) for half an hour at 4 °C. Sam-
ples were centrifuged at 180×g for 8 min and pellets
were stored at − 80 °C. Standard curves were made with
DNA of hMSC of the same donor before encapsulation.
DNA was determined with the CyQUANT® Cell Pro-
liferation Assay Kit (Invitrogen, Carlsbad, CA, USA)
following the manufacturer’s instructions. The fluores-
cence measurements were performed on a microplate
reader with excitation at 480 nm and emission detection
at 520 nm (Spectramax Gemini, Molecular Devices,
Sunnyvale, CA, USA).
LIVE/DEAD® assay (Invitrogen, Carlsbad, CA,
USA) was performed by incubating MSC-alginate
beads for 30 min in 100 μl labelling solution with 1.0
μL/mL green-fluorescent calcein-AM and 1.5 μL/mL
red fluorescent ethidium homodimer-1, at 37 °C. Z-
stacks were made using an Axiovert 200 MOT fluores-
cent microscope (Carl Zeiss microscopy, Thornwood,
NY, USA) with a thickness of 200 μm per slide. Viable
and dead cells were counted in two Z-stacks on two
areas of 0.25 mm2 per Z-stack using ImageJ 1.48 (Java,
Redwood Shores, CA, USA).
Immunomodulatory capacity
First, immunomodulatory capacity of the encapsulated
hMSC (using cells from 2 different bone marrow do-
nors) was determined by measuring interleukin-6 (IL-6)
protein levels and IDO activity. After 2 weeks of culture,
hMSC were stimulated with 50 ng/mL IFNγ and 50 ng/
mL TNFα (Peprotech, London, UK). For control, me-
dium without IFNγ and TNFα was added to encapsu-
lated hMSC. After 24 h, conditioned medium was har-
vested and stored at – 80 °C until analyses. IL-6 levels in
the stimulated and non-stimulated hMSC conditioned
media were measured by ELISA (R&D systems,
Abingdon, UK) according to the manufacturer’s instruc-
tions. IDO activity was determined in the stimulated and
non-stimulated MSC conditioned media by the level of
its metabolite L-kynurenine. This was measured spec-
trophotometrically as described previously (Kang et al.
2008).
The immunosuppressive capacity of encapsulated
hMSC was determined in a co-culture with activated
lymphocytes. The MSC-alginate beads (using MSC
from 1 bone marrow donor) were cultured for 2 days
and 29 days and then were stimulated with 50 ng/mL
IFNγ and 50 ng/mLTNFα for 24 h. The MSC-alginate
beads were washed two times with saline and 4, 2, or 1
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bead (approx. 3.0 × 104 hMSC per bead) was transferred
in a 48-well plate to obtain a 1:2.5, 1:5, and 1:10 MSC/
peripheral blood mononuclear cells (PBMCs) ratio.
PBMCs were isolated with Ficoll-Paque™ PLUS (den-
sity 1.077 g/mL; GE Healthcare, Uppsala, Sweden)
from buffy coats of healthy blood donors (Sanquin,
Rotterdam, The Netherlands) and frozen at − 150 °C
until further use. In total, 1.0 × 106 PBMCs/mL were
labelled with 1 μM carboxyfluorescein succinimidyl
ester (CFSE) and activated with antibodies against
CD3 and CD28 (1 μL per 1 × 106 cells in 1 mL, BD
Biosciences). As positive and negative lymphocyte pro-
liferation control, activated and non-activated CFSE-
PBMCs were used. As a positive control for immuno-
modulatory capacity of hMSC, 1.2 × 105 hMSC in
monolayer were used. After 5 days of co-culture,
PBMCs were retrieved, and incubated with CD4
(APC-A; BD Biosciences) and CD8 (PE-CY7-A; BD
Biosciences). Proliferation was determined from dilu-
tion of CFSE (FITC) staining using 8 colors
FACSCANTO-II with FACSDIVA Software (BD Bio-
sciences) and FlowJo Software (Tree Star Inc., Palo
Alto, CA).
Animal experiments
We performed three separate animal experiments to
assess influence ofMSC encapsulation on cell longevity
and effect of encapsulation on treatment efficacy. These
experiments were carried out in accordance with the EU
Directive 2010/63/EU for animal experiments. First, we
implanted rMSC-alginate (High G and High M) con-
structs subcutaneously in rats to asses construct integrity
and rMSC survival in vivo (experiment A, Fig. 1). In the
second in vivo experiment, we moved to the joint and
traced intra-articularly injected r(Fluc)MSC and
r(Fluc)MSC-alginate High G beads cross-linked in the
presence of gadolinium, over time to prove that we can
prolong the presence of rMSC at the desired location
(experiment B, Fig. 1). In the third experiment, we
studied the therapeutic efficacy of intra-articularly
injected hMSC either free or encapsulated in beads
(experiment C, Fig. 1). All experiments are explained
in further detail below. All experiments were performed
on 16-week-old male Wistar rats, weighing 250–300 g
(Harlan Netherlands BV, The Netherlands), with ap-
proval of the animal ethics committee (protocol no.
EMC116-15-02). Rats were housed in groups of two
per cage, under 12-h light-dark cycle at a temperature of
24 °C, and had access to water and food ad libitum at the
animal testing facilities of the Erasmus MC, University
Medical Center. Before the start of the experiments, rats
were allowed to acclimatize for a week. All procedures
involving subcutaneous implantations, intra-articular in-
jections, or scanning were applied under 2.5%
isoflurane anesthesia.
Subcutaneous implantation
The constructs of High G alginate and High M alginate
with rMSC were placed in saline and subcutaneously
implanted on the back of three rats. Each rat received
two constructs of High G alginate with rMSC and one
without cells and two constructs of High M alginate
with rMSC and one without cells. Directly and 12 h
after the operation, the rat got a subcutaneous injection
with buprenorphine (Temgesic) 0.01 mg/kg
bodyweight. To track the subcutaneously implanted
rMSC, they were labelled 1 day prior to encapsulation
in alginate with superparamagnetic iron oxide (SPIO)
using ferumoxides 100 μg/mL medium (Endorem™,
Guerbet S.A., Paris, France) complexed to protamine
sulphate 5 μg/mL medium (LEO Pharma N.V., Wilrijk,
Belgium) as described previously (van Buul et al. 2009).
Imaging of the MSC constructs was done by MR imag-
ing directly after implantation and thereafter weekly up
to 5 weeks. Five weeks after implantation, the rats were
euthanized. The subcutaneous implantation regions
were harvested, fixed in 0.05 M Tris-buffered saline
with 10 % formalin and 15 mM CaCl for 24 h and
embedded in paraffin.
Intra-articular cell tracking experiments
To evaluate bead integrity and the retention of encapsu-
lated cells in a diseased environment that is mechanical-
ly loaded, we induced knee OA in rats. Mono-
iodoacetate (MIA; 300 μg) was intra-articularly injected
bi-laterally in 25 μL of saline (van Buul et al. 2014)
using a 50-μL glass syringe (Hamilton Company,
Ghiroda, Romania) and a 27-G needle (Becton, Dickin-
son and Company, Benelux N.V. Belgium). One week
after OA induction (referred to as day 0), rats were
randomly divided into two treatment groups: (1) freely
injected 1.0 × 105 r(Fluc)MSC (n = 8 knees), and (2)
approx. 1.0 × 105 r(Fluc)MSC encapsulated in
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gadolinium-labelled High G alginate beads (n = 8).
Beads and loose cells were both injected in a total
volume of 25 μL saline. These injections were done
with a 250-μL glass syringe and a custom made 23-G
needle (Hamilton Company, Ghiroda, Romania). The
choice of this relatively low cell number was based on
the assumption that with longer presence of cells the
number of cells needed for a therapeutic effect would be
lower. In a previous study, we found an analgesic effect
of 1.0 × 106 freely injected cells in the same OA model
(van Buul et al. 2014).
To follow up cell viability and alginate bead integrity,
weekly bioluminescence and MR imaging were per-
formed (methods see below). Animals were scanned
once directly after injection of the cells and hereafter
once a week for a total of 8 weeks. Animals were
euthanized 8 weeks after treatment.
Intra-articular hMSC efficacy experiment
Bilateral OAwas induced as described above. One week
after OA induction (referred to as day 0), rats were
randomly divided into three treatment groups, and rats
received in both knees the same treatment, except one
animal which received free hMSC in one knee and
saline control in the contra-lateral knee resulting in three
groups: (A) saline control (n = 19); (B) 1.0 × 105 freely
injected hMSC (n = 19); (C) 0.8 × 105 ± 0.1 × 105
hMSC encapsulated in alginate beads (n = 22). MSC
from 3 human donors were pooled to take into account
Fig. 1 Experimental set up of in vivo experiments to evaluate the
effect of encapsulation of MSC in alginate on cell viability and
efficacy to treat OA. In experiment A, allogeneic rMSC-alginate
constructs and empty alginate constructs were implanted subcuta-
neously in rats to assess construct integrity and MSC survival
in vivo. In experiment B, longevity of MSC in an OA knee joint
was tested using allogenic r(Fluc)MSC either free or encapsulated
in alginate beads. Weekly imaging with MRI for construct
integrity and BLI for cell viability followed until the end of the
experiment at week 8. In experiment C, the therapeutic efficacy of
hMSC in an OA knee joint was studied. hMSCwere injected intra-
articularly either free or encapsulated in alginate beads and com-
pared with saline control. The effect on pain was measured weekly
and knees were harvested for histology at week 4 (synovial in-
flammation) and week 8 (synovial inflammation and cartilage
damage)
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the inter-donor variability. Four weeks after treatment,
the animals were euthanized to assess the effects of our
treatments on synovial inflammation and knee joints
were prepared for histological evaluation (n = 6 knees/
group). The remaining animals were euthanized 8 weeks
after start of treatment and knee joints were harvested
for histological analysis (n = 16 knees/group). In the
latter group, pain was evaluated weekly with mechani-
cal allodynia tests (method see below).
Imaging
Bioluminescence imaging (BLI)
To evaluate the presence of living cells over time, lucif-
erase activity of injected r(Fluc)MSC was measured
using the Xenogen IVIS Spectrum (PerkinElmer,
Hopkington, MA), 15 min after intra-peritoneal injec-
tion of 50 μg beetle luciferin in 150 μL saline (Promega
Benelux B.V., Leiden, the Netherlands). Optical inten-
sity is reported as arbitrary units. Data were analyzed
using the software Living Image version 3.2 (Caliper
LS).
Magnetic resonance imaging (MRI)
MR imaging was performed on a preclinical 7.0-T MRI
scanner (MR 901 Discovery, Agilent/GE Healthcare,
Milwaukee, WI). For imaging SPIO-labelled rMSC, a
72-mm transmit/receive body coil was used. Image
acquisition was performed using a fast spoiled gradient
echo sequence with the following parameter settings:
TE/TR = 1.1/7.3 ms, NEX = 4, FOV 8 × 6 cm2,
acquisition matrix 256 × 192, slice thickness = 1 mm,
bandwidth = 60 kHz, 16 degrees. Sagittal and coronal
scans were performed to localize the hypo-intense SPIO
deposits.
For intra-articular localization of alginate beads and
to follow up the presence of these beads in vivo, we used
gadolinium in the alginate beads and scanned with a
150-mm body coil for transmission, and a four-channel
cardiac coil (Rapid BiomedGmbH, Rimpar, Germany)
for signal reception. A 3D, fast spoiled gradient echo
sequence was used to scan the injected rat knees (TE/TR
10.0/30.0 ms, NEX 2, FOV 6.00 × 4.50 cm2, acquisition
matrix 512 × 512, slice thickness 0.50 mm, bandwidth
31.25 kHz, flip angle 16°). The number of beads per
knee was counted manually using the built-in DICOM
viewer on the scanner (Software build 1094.1, General
Electric Healthcare, Milwaukee, WI).
Pain assessment
Hind paw withdrawal reflex was measured with von
Frey filaments (Bioseb, France) as an indicator of pain
(Koda et al. 2014). Animals were habituated to measur-
ing cages and handling by the examiner starting 2 weeks
prior to OA induction. The hind paws of the rats were
stimulated using a series of von Frey filaments, increas-
ing in strength starting at 0.2 to a maximum of 26 g. If
the paw was withdrawn after the administration of the
von Frey filament for a minimum of 4/5 times, the
strength of the filament was noted. If no reaction was
seen after 5 attempts, for a maximum of 3 s each, a
stronger filament was used until a response was mea-
sured. A baseline measurement was performed after the
rats were habituated and just before OA induction.
Follow-up measurements were performed 7 days after
OA induction, which was just before therapy adminis-
tration, and thereafter once weekly until the end of the
experiment at 8 weeks. All measurements were per-
formed by the same examiner, blinded for the treatment
groups, in the same room, with temperature set at 18–20
°C and the same background noises present at time of
measurement. Measurements were performed at the
same time of day.
Histology
Evaluation of subcutaneously implanted MSC-alginate
constructs
Paraffin sections (6μm)were deparaffinised and stained
for Perls’ iron according to the manufacturer’s protocol
(Klinipath BVBA, Duiven, The Netherlands) to locate
the SPIO-rMSC. SPIO-labelled rMSC are stained blue
with Perls’. CD68 and CD3 staining was performed to
identify macrophages and T lymphocytes as an indica-
tion of a local inflammatory response. Antigen retrieval
for CD68 and CD3 was performed through incubation
in citrate buffer (10 mM citric acid, 0.05% Tween20, pH
6.0) for 20min at 90–95 °C. Sections were incubated for
1 h with primary antibodies for CD68 (BM4000 5 μg/
mL; OriGene Technologies, Herford) or CD3
(Ab16669, dilution 1:100; Abcam Cambridge, UK) di-
luted in PBS/1%BSA (Sigma no. A7284) after blocking
of non-specific binding sites with 10 % goat serum
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(Southern Biotech no. 0060-01) in PBS/1%BSA. A
secondary antibody biotinylated goat anti-mouse 1:50
(Biogenex, HK-325-UM) was used, followed by incu-
bation with streptavidin-AP 1:50 (Biogenex, HK-321-
UK). Staining was then visualized using an alkaline-
phosphatase substrate followed by counterstaining with
hematoxylin.
Evaluation of knee joints after MSC-alginate bead
injection
Knees were fixed in formalin 4% (v/v) for 1 week,
decalcified in 10% EDTA for 2 weeks, and embedded
in paraffin, and coronal sections of 6 μm were cut.
Sections were collected anterior to posterior every
300 μm to give a good overview of the damage through-
out the entire knee. Cartilage damage was evaluated on
Safranin O-stained sections, with a scoring system de-
scribed by Pritzker et al. (2006). Scoring was done on
three sections aiming around the mid-portion of the
joint. The Pritzker score ranges from 0–6 for structural
damage and 0–4 for GAG staining intensity. These
scores were multiplied with a factor 1–4 to account for
the percentage of surface affected (factor 1, 0–25%; 2,
26–50%; 3, 51–75%; 4, 76–100% surface area). This
led to a maximum score of 24 for structural damage and
a maximum of 16 for GAG loss, as described previously
by van Buul et al. (2014) The scoring of two blinded
observers was averaged and used for data analyses.
Synovial inflammation was evaluated on sections
stained with hematoxylin–eosin. The sections were im-
aged using NanoZoomer Digital Pathology program
(Hamamatsu Photonics, Herrsching am Ammersee,
Germany), and synovial thickness was measured from
the capsule to the superficial layer of the synovial mem-
brane in the parapatellar recesses at the medial and the
lateral sides at three positions per section, as previously
described Khatab et al. 2018a; Khatab et al. 2018b).
These measurements were performed on three sections
per knee, with 300 μm between the sections. The thick-
ness measurements were averaged to obtain a single
value per knee joint.
Statistical analysis
Data was analyzed with IBM SPSS statistics 24 (SPSS,
Chicago, IL). To evaluate the in vitro data of DNA, live/
dead cell count, IL-6 secretion, IDO activity, and lym-
phocyte proliferation of MSC-alginate beads, Mann-
Whitney U tests were performed. To evaluate the num-
ber of alginate beads on MRI scans of rat joints over
time, a Wilcoxon signed-rank test was performed, since
data did not meet requirement for normality with the
Shapiro-Wilk test. To compare fluorescence intensity of
r(Flu)MSC in the free MSC group vs. the MSC-alginate
group, a Mann-Whitney U test was performed, since
data did not meet the requirement of equal distribution
and normality with the Shapiro-Wilk test. To evaluate
the fluorescence intensity within groups over time, a
Wilcoxon signed-rank test was performed. For treat-
ment effects on pain, all groups were compared using
a linear mixed model in which measurement time point
and treatment were considered fixed factors and with-
drawal threshold a dependent factor. After significance
was confirmed, a one-way ANOVA was performed to
determine differences between groups. To determine
differences over time per treatment, a linear mixed mod-
el analysis was performed in which measurement time
point was considered a fixed and withdrawal threshold a
dependent factor. Post hoc analysis using Bonferroni
correction was performed.
For synovial inflammation, homogeneity of vari-
ances and normality were confirmed with a Shapiro-
Wilk test. Next an one-way ANOVA was performed;
post hoc analyses were performed and Bonferroni cor-
rection was applied.
For non-parametric cartilage scoring data, Mann-
Whitney U tests were used to assess MIA or measure-
ment time point effects. Kruskal Wallis tests were used
for treatment effects within time points. Post hoc analy-
ses were performed by Bonferroni correction. For all
tests, p values < 0.05 were considered statistically
significant.
Results
MSC remain viable and immunomodulatory active
in both clinical grade High M alginate and High G
alginate
The amount of DNA measured in the beads after 2
weeks was 45.4% in High M alginate (p = 0.01) and
57.4% in High G alginate (p = 0.04) of the amount at the
moment of encapsulation (Fig. 2a). No significant dif-
ference was found in the amount of DNA between High
M alginate and high G alginate constructs. The number
of viable cells was not significantly different between
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Fig. 2 Viability and immunomodulatory capacity of encapsulated
MSC in High G alginate and High M alginate. a DNA amount
directly after encapsulation or after 2 weeks. b Number of viable
cells directly after encapsulation and after 2 weeks. c IL-6 secre-
tion and d IDO activity measured as concentration of L-kynurenine
in the medium after stimulation with IFNγ/TNFα (a–d all per-
formed with hMSC of 2 different donors with 3 samples per
donor). Activated CD4+/CD8+ T lymphocytes co-cultured with
one, two, and four hMSC-alginate constructs with e High M or f
High G alginate, 3 days and 30 days after encapsulation of hMSC
(performed in triplicate with samples of 1 hMSC donor and 1
PBMC donor). First bar: non-stimulated PBMCs; positive control.
Second bar: stimulated PBMC without alginate constructs. Third
bar: stimulated PBMC in the presence of 1.2 × 105 hMSC in
monolayer. Fourth bar: stimulated PBMC in the presence of empty
alginate constructs. Mean ± SD is shown * indicates statistical
significance
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High M and High G alginates directly after encapsula-
tion or after 2 weeks in culture (Fig. 2b).
hMSC encapsulated in either alginate retained their
immunomodulatory capacities when stimulated with
IFNγ and TNFα. This stimulation induced IL-6 secre-
tion (Fig. 2c) and IDO activity (Fig. 1d) from the en-
capsulated MSC irrespective of the type of alginate
used. Alginate-encapsulated hMSC significantly
inhibited proliferation of stimulated CD4+ and CD8+
T lymphocytes. Three days after encapsulation hMSC
encapsulated in High G and High M alginates (Fig.
2e, f) significantly inhibit T lymphocyte proliferation
in a dose-dependent manner (all p = 0.024). Thirty days
after encapsulation, inhibition was reduced but in par-
ticular still present in High G alginate when four and
two beads were used (p = 0.024) (Fig. 2f). Empty
constructs of alginate had no effect on T cell prolifera-
tion. The inhibition by 1.2 × 105 hMSC in monolayer
was similar to the inhibition of 4 alginate constructs,
containing a similar number of MSC on day 0.
No difference in construct integrity and MSC retention
after in vivo implantation of encapsulated allogeneic
MSC in High M alginate and High G alginate
Subcutaneously implanted alginate-encapsulated SPIO-
MSC remained clearly visible on MR images over 5
weeks (Fig. 3a, b) and where clearly visible macroscop-
ically upon explantation (Fig. 3c) without noticeable
differences between high M and high G alginate con-
structs. As observed in histological sections, there was
good integrity of the constructs (Fig. 3d–g) and a ho-
mogenous distribution of SPIO-labelled cells in alginate
constructs (Fig. 3h–k). The rat tissue surrounding the
constructs showed very limited foreign body reaction
without cell infiltration of macrophages (CD68; Fig.
3h–k) or T lymphocytes (CD3; Fig. 3l–o). No differ-
ences in construct morphology or foreign body reaction
were observed between High M alginate and High G
alginate.
Alginate encapsulation using a micro-encapsulator
results in small injectable beads with vital MSC.
After optimizing the settings of the encapsulator device,
we were able to produce homogenous beads of 0.3 mm
using High G alginate. With the more viscous High M
alginate, the beads were larger and the size was less
homogenous. We decided to continue with High G
alginate. The average bead size produced with High G
alginate was 284 ± 28 μm, with each bead containing
112 ± 32 MSC (Fig. 4a, b). To confirm that the anti-
inflammatory capacity of the hMSC was not affected by
the procedure with the micro-encapsulator, we per-
formed an IDO assay on the secretome of the stimulated
hMSC. We compared hMSC in monolayer vs. hMSC-
encapsulated in alginate beads (n = 3 donors). Encapsu-
lated hMSC displayed similar IDO activity compared
with hMSC in monolayer (L-kynurenine concentration;
48.91 ± 10.67 μM vs. 45.63 ± 1.17 μM respectively
using equivalent numbers of cells) (Fig. 4c). This indi-
cates that after cell encapsulation, hMSC maintained
anti-inflammatory capacities.
Intra-articularly injected MSC-alginate beads remain
present and metabolically active in the joint for at least 8
weeks in vivo
Unfortunately, one rat of the group with alginate died
during imaging at day 0 probably due to anesthesia-
related issue and the results of these knees were exclud-
ed from analyses. The other animals were longitudinally
followed by imaging in MRI and BLI during 8 weeks.
To track the MSC-alginate beads in vivo, alginate
was cross-linked with gadolinium ions which are visible
on MRI. At baseline, the number of alginate beads per
knee was 73 ± 36 (Fig. 5a, b). A majority of the alginate
beads were located in the suprapatellar pouch. On
follow-up scans, the alginate beads appeared more dis-
persed throughout the joint. The number of beads de-
creased to 46 ± 34 per knee at week 4 (p = 0.028
compared with week 0), and remained stable afterwards
until the end of the experiment at week 8 (37 ± 20). To
track long-term cell activity after intra-articular injec-
tion, we used bioluminescence (BLI) scanning of allo-
geneic r(Fluc)MSC that were either encapsulated in
alginate beads before injection (n = 6 knees) or freely
injected in the knee (n = 8). The first scan was
preformed immediately after injection (Fig. 5c) and
subsequently scanned repeatedly until week 8. The
BLI signal in the r(Fluc)MSC-alginate group was lower
than expected based on cell number at day 0, most likely
due to impaired metabolic activity of the cells shortly
after encapsulation in alginate which is supported by a
higher BLI signal after 2 weeks. BLI signal decreased
significantly from week 2 to week 3 (p = 0.028) but
remained stable hereafter (p > 0.293). From week 3 on,
the fluorescence in the r(Fluc)MSC-alginate group was
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significantly stronger than that in the free r(Fluc)MSC
group (p < 0.04 for all time points (Fig. 5c, d).
Encapsulation in alginate did not improve effect
of hMSC on pain, cartilage damage, or synovial
inflammation
To test the efficacy of the hMSC-alginate beads as
therapy for osteoarthritis, we assessed the effect on
pain reduction, cartilage damage, and synovial inflam-
mation in a rat OAmodel. Pain was assessed by means
of tactile allodynia using the von Frey filaments. Prior
toMIA injection, all the animals had comparable with-
drawal thresholds. One week after MIA injection and
before treatment, all three treatment groups (saline
control, free hMSC, and hMSC-alginate beads)
showed a significant decrease in withdrawal threshold
(p < 0.02), indicating pain as a result of MIA injection.
Fig. 3 Subcutaneous implanted allogeneic rMSC in immunocom-
petent rats. a MRI image directly after implantation and b MRI
image of the same animal 5 weeks after implantation. Alginate
constructs are visible due to the labelled SPIO cells in the con-
structs. c After 5 weeks, the constructs were clearly visible after
removal of the skin post-mortem. d–g Hematoxylin and eosin-
stained tissue sections of biopsies taken at the site of the SPIO-
labelled-MSC-containing construct implants of highM and highG
alginate constructs. h–k Staining of corresponding sections shown
in d–g with Perl’s iron staining (blue), which stains SPIO com-
bined with CD68 staining (red) to stain macrophages. l–o CD3
staining (red) to stain T lymphocytes (black dots in cells represent
SPIO particles)
Cell Biol Toxicol
Oneweek after treatment, only the animals in the saline
control group showed an additional significant de-
crease in withdrawal threshold compared with the time
point just before treatment (p = 0.001), indicating ex-
acerbating pain over time. No increase in sensitivity to
pain stimuluswasobserved in the free hMSCorhMSC-
alginate beads group. Although rats in the free hMSC
group showed a trend toward less pain in time, a sig-
nificant difference compared with the saline-treated
group was only reached at the end of the experiment
Fig. 4 Characteristics of MSC-alginate beads produced with
micro-encapsulator device. a hMSC-alginate beads prepared with
the micro-encapsulator. b The average diameter of the alginate
beads and number of hMSC/bead. C Concentration of L-
kynurenine as measure of IDO activity corrected for the number
of cells in the secretome of MSC stimulated with TNFα/IFN
Fig. 5 In vivo cell tracking. a
MRI of rat knee joints injected
with gadolinium-labelled alginate
beads, directly after intra-articular
injection and after 8 weeks. b
Quantification of the number of
alginate beads per joint over time.
(Due to technical problems with
the MRI scanner, week 2 and 3
scans were not available). c BLI
of free r(Fluc)MSC and
r(Fluc)MSC-alginate bead direct-
ly after injections and after 8
weeks. d Quantification of BLI
signal over time (due to technical
problems with the IVIS, week 1
scans were not available). The
images shown in a and c are rep-
resentative animals for each
group. In a: P = patella, F= femur,
T = tibia. In d: white bars = free
(Fluc)MSC and black bars =
r(Fluc)MSC-alginate beads. (b, p
< 0.04; c, p = 0.028). n = 8 knees
for free r(Fluc)MSC and n = 6
knees for r(Fluc)MSC-alginate
group. N.D. = not determined due
to technical error. n.s. = not
significant
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Fig. 6 Therapeutic efficacy of
MSC-alginate beads in a rat OA
model. a Hind limb withdrawal
threshold as measure of pain over
time. bWithdrawal threshold 1
week after treatment. c A repre-
sentative example of the Safarin-
O staining at the femorotibial
compartment and d at the
patellofemoral compartment. e
The structural damage according
to the Prizker score and GAG loss
for femorotibial; f structural dam-
age and GAG loss in patella. The
maximum score for structural
damage was 24 and for GAG loss
16, in which a higher score rep-
resents more damage. g HE
staining of parapatellar recesses
and indication of synovial mem-
brane thickness. h–i Some degra-
dation and encapsulation of algi-
nate was observed (black arrows).
j Quantification of synovial
thickness over time (a p < 0.02, b
p = 0.036, c p = 0.001). All data
shown as mean ± SD. At week 4,
n = 5 knees/group; week 8, n = 16
knees/group
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atweek8 (saline control vs. free hMSC,p=0.036). The
hMSC-alginate beads group was not significantly dif-
ferent fromsaline control or free hMSCatweek 8 (resp.
p= 0.404 and p= 0.722), or any other week (Fig. 6a, b).
Cartilage damage was scored 8 weeks after treatment
on the femorotibial compartment of the joint as well as
the patella using a modified Pritzker score method. Mild
osteoarthritic changes were present in all groups. There
were no significant differences in cartilage damage or
GAG loss between treatment groups (Fig. 6c–f).
As an indicator of inflammation, we performed
thickness measurements of the synovial membrane
at the para-patellar recesses at 4 and 8 weeks after
start of treatment (Fig. 6g, h). No significant dif-
ferences between groups were found at week 4 (p
= 0.198) The hMSC-alginate group showed a trend
toward a thicker membrane at week 8 (p = 0.058)
and more infiltration of inflammatory cells next to
encapsulation of alginate remnants (black arrows
in Fig. 6i, j) compared with the saline control and
free hMSC group. To examine if alginate would
induce inflammation in the joint, we injected emp-
ty alginate beads intra-articularly in 2 additional
healthy rat knees. One week after injection, syno-
vial inflammation was seen on histology, charac-
terized by synovial hypercellularity and encapsula-
tion of the alginate beads, indicating a mild for-
eign body reaction against the alginate (Fig. 7).
4. Discussion
MSC have previously been described to have a benefi-
cial effect in regenerative medicine, both in pre-clinical
and some initial clinical studies, although evidence for
long-term engraftment is low (van Buul et al. 2014;
Diekman et al. 2013; Mak et al. 2016; Prockop 2009;
von Bahr et al. 2012). This led Prockop et al. and von
Bahr et al. to postulate the “hit-and-run” mechanism
(Prockop 2009; von Bahr et al. 2012) which proposes
the cells to only have a short interaction with the micro-
environment. The design of the current study is based on
the idea that the therapeutic efficacy of MSC could be
enhanced by prolonging the local presence of MSC and
their secreted factors at the desired location. To achieve
this purpose, we encapsulated MSC in alginate and
demonstrate that the cells remained viable in this carrier,
and are protected against the allogeneic immune system
and retained immunomodulatory capacity when stimu-
lated by external cytokines or immune cells. Moreover,
we demonstrate retention of construct integrity in vivo
over time by longitudinal MRI. For this purpose, gado-
linium was used to cross-link the alginate. By combin-
ingMRI with BLI of constructs that contained luciferase
transfected cells, we showed that encapsulation of MSC
is beneficial for in vivo cell survival and that it
prolonged their local presence in a diseased and in-
flamed environment.
Fig. 7 Empty alginate microbeads in healthy rat knees. HE staining one week after injection. (A+B)synovial thickening, encapsulation of
the alginate beads. (C) hypercellularity in the synovium. Arrow indicate alginate. The shape of the beads may have changed due to the
processing for histological analysis
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We used two types of alginate to encapsulate cells,
both were clinical grade but differed in composition
with respect to the ratio of guluronate and mannuronate.
With both alginate types, MSC retained their immuno-
modulatory capacity in vitro. The results are similar to
our previous study where we used a different type of
alginate that had a low viscosity and less well-defined
composition (Leijs et al. 2017). As there is a great
variability in the ratio of mannuronate and guluronate
between different types of alginate that are
(commercially) available, our work in which we used
high-quality GLP produced High G and High M algi-
nates demonstrates that a wide range of alginates might
be suitable for encapsulation. Different alginates have
different viscosities which can greatly influence the
mechanical properties of the construct and thus its in-
tegrity and the infiltration of cells. After subcutaneous
implantation in immune competent rats, constructs of
High G and High M alginates remained intact with a
thin capsule formed around the construct. There was no
infiltration of immune cells in the alginate. We took the
alginate-encapsulated MSC a step further by evaluating
them in a diseased situation: in our case, in rat knees
after induction of osteoarthritis. To provide an injectable
therapy, we optimized a protocol using a machine for
encapsulation that enabled reproducible generation of a
homogeneous population of MSC-alginate microbeads,
with an average diameter below 300 μm. The size of
these constructs contributes to easy clinical application
since they are small enough to pass through a 23G
needle that can be used for most clinical applications.
The use of gadolinium, with its contrast properties in
MR imaging (Lux and Sherry 2018), made it possible to
monitor localization and integrity of the alginate con-
structs over time. Gadolinium was incorporated in the
guluronate or mannurate molecules upon polymeriza-
tion, and loss of gadolinium signal was attributed to loss
of construct integrity. Quantification with MRI of the
Gd-labelled beads indicated an initial loss of some beads
with subsequent retained visible presence of approxi-
mately half of the alginate beads up to the end of the
experiments at 8 weeks post-injection. Although we
cannot exclude that the loss of Gadolinium signal is
caused partly by diffusion of gadolinium out of the bead,
under in vitro conditions leakage of gadolinium out of
the alginate beads was not seen at all during a 3-week
follow-up period (data not shown). Therefore, we as-
sume that lessening of the number of visible beads is due
to disintegration of the beads with concomitant release
and loss of hMSC. The latter is confirmed by the BLI
data that showed a matching decrease in cell signal over
time. A substantial part of the cells, however, remained
present until the end of the study. Possibly, some beads
are lost due to mechanical forces in the joint during
movement of the animal. We speculate that this problem
might be less in a larger joint where the beads have more
space to be distributed to a relatively sheltered position,
such as in the suprapatellar pouch, where high loading
that occurs between cartilage surfaces can be avoided.
The unique option to follow bead integrity on MRI,
while having the anatomy of the joint visible in the same
image, provides a safe and helpful tool to follow algi-
nate constructs, also in a clinical setting in human,
equine, or canine patients. The method might be useful
for in vivo tracking of other materials that polymerize
with divalent cations such as fibrin.
Besides bead and cell tracking to demonstrate
prolonged cell presence, we tested therapeutic effica-
cy of the encapsulated MSC in a rat model for OA.
Although we have previously shown MSC retain
osteogenic and adipogenic differentiation capacity
after 30 days of alginate encapsulation (Leijs et al.
2017), we hypothesize that therapeutic effect of
MSCs is mainly by secretion of factors. In previous
work, we have shown that multiple intra-articular
injections of MSC secretome can inhibit pain and
have a protective effect on cartilage damage in a
mouse OA model (Khatab et al. 2018b). This con-
firms that MSC-based treatments can exert their ef-
fects in vivo by their secretome and do not rely solely
on cell–cell contact or their differentiation capacity.
In this study, we quantified the stimulation-induced
IL-6 secretion and IDO activity from the encapsulat-
ed hMSC. This is, however, only a small fraction of
the biologically active factors that are secreted by
MSC, either soluble or in extracellular vesicles. It
is, therefore, important to test the functionality of
the secreted factors, which we did by demonstrating
that these encapsulated hMSC significantly inhibited
proliferation of stimulated CD4+ and CD8+ T lym-
phocytes in a dose-dependent manner.
Preferably, a continuous interaction and feedback loop
between the diseased tissue and the exogenous MSC is
created, in order to produce cytokines and growth factors at
the right time and in the right concentration. Based on the
longer presence, we choose to inject 1 × 105 cells per joint.
This number is ten times lower than what we injected
previously in the same rat OA model (van Buul et al.
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2014). Possibly as a consequence of that, in our study a
therapeutic effect of freely injected human MSC was not
detectable. The encapsulated MSC, however, did not do
better than the freely injected MSC. This absence of im-
proved therapeutic effect by encapsulation could be due to
an insufficient number of cells. Maybe, initially a larger
cell number is needed to reduce the inflammation. The
small size of the rat joint, however, did not allow injection
of more beads. Because preliminary experiments had in-
dicated the density of 4 million cells/mL to be a good
balance between concentration of secreted factors and
stability of the gel construct, we have not considered using
higher cell numbers per bead. Furthermore, we have cho-
sen to use human MSC for this study to increase the
clinical translatability of a human allogeneic MSC-
alginate construct. A disadvantage of the use of xenoge-
neic MSC in this setup could be that some important
factors and cytokines might not be interspecies conserved.
This can cause in vivo miscommunication between xeno-
geneic MSC and the diseased environment. Since we and
others have seen anti-inflammatory effects of xenogeneic
MSC secretome alone, we can conclude that the secreted
factors of xenogeneic MSC are capable of at least achiev-
ing anti-inflammatory and chondroprotective effects inOA
(Khatab et al. 2018a). Nevertheless, it is still possible that
the use of xenogeneicMSC depreciates the full potential of
MSC therapy, an issue that could be tackled by using
allogenic MSC. The use of xenogeneic MSC could also
explain the discrepancy between our work and the recently
published work of Choi et al., showing promising results
using allogenic encapsulated MSC in a rabbit OA model,
although in that study no cell or construct tracking was
performed (Choi et al. 2018).
Although the use of alginate encapsulation is prom-
ising in the field of regenerative medicine, it might bring
safety and regulatory issues. Although the fibrous cap-
sule formed around the alginate implants when im-
planted subcutaneously was very thin and the constructs
remained completely intact, upon injection in the joint,
we noticed a trend to synovial thickening and the algi-
nate beads were encapsulated in the synovial membrane.
This reaction, even though it was not a strong foreign
body response, might have dampened the anti-
inflammatory effect of MSC and in extension its effect
on pain. Since this reaction seemed less strong after
subcutaneous implantation of MSC-alginate or empty
alginate constructs, it might be caused by mechanical
damage to the constructs or the presence of local inflam-
mation in the osteoarthritic joint. If the alginate is
compromised and starts to slowly release the xenogene-
ic hMSC, an adaptive immune response can be initiated,
further reducing the therapeutic potential. Although im-
mune privileged, MSC do maintain a degree of immu-
nogenicity (Schu et al. 2012). This foreign body reaction
leads possibly to a slow release of xenogenic MSC out
of the alginate, possibly causing a chronic local inflam-
mation. Thus, to limit this reaction, two factors play an
important role: the biomaterial (the alginate) and the
MSC. Focusing on the biomaterial, it is possible that a
different type of alginate could be more resistant to
damage in the osteoarthritic joint. This would prevent
the release of xenogeneic hMSC, thus the adaptive
immune response, and decrease the fibrous tissue for-
mation as seen in our experiments. Another way to
decrease this reaction is to use autologous MSC: this
would further inhibit the graft vs. host disease. Of
course, extensive in vitro and in vivo experiments are
needed to investigate these hypotheses.
In conclusion, we have provided a method to produce a
homogenous gadolinium-labelled cell-alginate construct
combined with imaging techniques that are suitable for
minimal invasive longitudinal follow-up studies in patients.
We showed that non-autologous MSC can survive longer
and remain metabolically active in vivo up to at least 8
weeks when encapsulated in alginate. The possibility to
retain non-autologous cells and the production of standard-
ized small beads greatly increased the feasibility of produc-
ing cell-alginate microcapsules in a standardized safe way
and, on a large scale, giving it the potential of an “off-the-
shelf” biological therapeutic option. These are both impor-
tant additional steps toward clinical applicability. Unfortu-
nately, the overall treatment effect on pain, synovial inflam-
mation, and cartilage quality in this study could not be
confirmed in our in vivoOAmodel, possibly due to specific
local tissue responses to the alginate beads or a suboptimal
cell number. Our results encourage further development of
this strategy to provide an injectable therapy by cell encap-
sulation that greatly prolongs the interplay between the
therapeutic cells and their diseased target tissues, taking into
account specific local and disease requirements.
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